Methods and compositions relating to microbial treatment and diagnosis of skin disorders

Abstract

The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The disclosure provides compositions and methods for the treatment of skin disorders using microbial compositions to a subject.

1 . A method of treating a skin disorder in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically-effective amount of a population of isolated and purified microorganisms. 
     
     
         2 . The method of  claim 1 , wherein said population of isolated and purified microorganisms comprises a microorganism that modulates a pH of the subject. 
     
     
         3 . The method of  claim 2 , wherein said microorganism modulates the pH of the skin of the subject. 
     
     
         4 . The method of  claim 1 , wherein said skin disorder is atopic dermatitis. 
     
     
         5 . The method of  claim 1 , wherein said population of isolated and purified microorganisms comprises a microorganism that produces vinegar. 
     
     
         6 . The method of  claim 1 , wherein said population of isolated and purified microorganisms comprises a microorganism that produces hydrogen peroxide. 
     
     
         7 . The method of  claim 1 , wherein said treating results in an altered microbiome in said subject. 
     
     
         8 . The method of  claim 1 , wherein said treating results in a reduction of a pH of said subject. 
     
     
         9 . The method of  claim 8 , wherein said reduction comprises reducing said pH to a range from about pH 4.0 to about pH 7.0. 
     
     
         10 . The method of  claim 1 , wherein the pharmaceutical composition is formulated for oral administration. 
     
     
         11 . The method of  claim 1 , wherein the pharmaceutical composition is formulated for topical administration. 
     
     
         12 . The method of  claim 1 , wherein the pharmaceutical composition further comprises vinegar. 
     
     
         13 . The method of  claim 1 , wherein the pharmaceutical composition further comprises trans-urocanic acid. 
     
     
         14 . The method of  claim 1 , wherein the pharmaceutical composition further comprises a metabolite. 
     
     
         15 . The method of  claim 1 , wherein the pharmaceutical composition further comprises an anti-microbial peptide. 
     
     
         16 . The method of  claim 1 , wherein the pharmaceutical composition further comprises a bacteriocin. 
     
     
         17 . The method of  claim 1 , wherein the pharmaceutical composition further comprises an enzyme. 
     
     
         18 . The method of  claim 1 , wherein the pharmaceutical composition further comprises a prebiotic. 
     
     
         19 . A pharmaceutical composition comprising a population of isolated and purified microorganisms, wherein said population of isolated and purified microorganisms comprises a microorganism that modulates pH. 
     
     
         20 .- 35 . (canceled) 
     
     
         36 . The method of  claim 1 , wherein said population of isolated and purified microorganisms comprises a microorganism with a rRNA sequence comprising at least about 85% sequence identity to a rRNA sequence of a microorganism selected from the group consisting of:  Akkermansia muciniphila, Anaerostipes caccae, Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium longum, Butyrivibrio fibrisolvens, Clostridium acetobutylicum, Clostridium aminophilum, Clostridium beijerinckii, Clostridium butyricum, Clostridium colinum, Clostridium coccoides, Clostridium indolis, Clostridium nexile, Clostridium orbiscindens, Clostridium propionicum, Clostridium xylanolyticum, Enterococcus faecium, Eubacterium hallii, Eubacterium rectale, Faecalibacterium prausnitzii, Fibrobacter succinogenes, Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus caucasicus, Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus lactis, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Oscillospira guilliermondii, Roseburia cecicola, Roseburia inulinivorans, Ruminococcus flavefaciens, Ruminococcus gnavus, Ruminococcus obeum, Stenotrophomonas nitritireducens, Streptococcus cremoris, Streptococcus faecium, Streptococcus infantis, Streptococcus mutans, Streptococcus thermophilus, Anaerofustis stercorihominis, Anaerostipes hadrus, Anaerotruncus colihominis, Clostridium sporogenes, Clostridium tetani, Coprococcus, Coprococcus eutactus, Eubacterium cylindroides, Eubacterium dolichum, Eubacterium ventriosum, Roseburia faeccis, Roseburia hominis, Roseburia intestinalis, Lacatobacillus bifidus, Lactobacillus johnsonii , and any combination thereof. 
     
     
         37 . The method of  claim 1 , wherein said pharmaceutical composition further comprises hydrogen peroxide. 
     
     
         38 . The method of  claim 18 , wherein said prebiotic is selected from the group consisting of: complex carbohydrate, complex sugar, resistant dextrin, resistant starch, amino acid, peptide, nutritional compound, biotin, polydextrose, oligosaccharide, polysaccharide, fructooligosaccharide (FOS), fructan, soluble fiber, insoluble fiber, fiber, starch, galactooligosaccharides (GOS), inulin, lignin, psyllium, chitin, chitosan, gums, high amylose cornstarch (HAS), cellulose, β-glucan, hemi-cellulose, lactulose, mannooligosaccharide, mannan oligosaccharide (MOS), oligofructose-enriched inulin, oligofructose, oligodextrose, tagatose, trans-galactooligosaccharide, pectin, resistant starch, and xylooligosaccharide (XOS), and any combination thereof. 
     
     
         39 . The method of  claim 18 , wherein said prebiotic is a polysaccharide. 
     
     
         40 . The method of  claim 1 , wherein the population of isolated and purified microorganisms comprises a microorganism that increases butyrate production in the subject. 
     
     
         41 . The method of  claim 1 , wherein the population of isolated and purified microorganisms comprises a microorganism that modulates short-chain fatty acid production in the subject.